TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01454115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Capsule, Oral, 50 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163 (Gamma-Secretase Inhibitor)
Description: Oral Solution, Oral, 800 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Oral Solution, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Capsule, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Capsule, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Capsule, Oral, 0 mg, Once daily, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-708163
Description: Capsule, Oral, 0 mg, Once daily, once
Study: NCT02180269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (25 mg)
Description: Single oral dose of JNJ-54861911, 25 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (50 mg)
Description: Single oral dose of JNJ-54861911, 50 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 (100 mg)
Description: Single oral dose of JNJ-54861911, 100 mg on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo matched to JNJ-54861911 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo matched to JNJ-54861911 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of placebo matched to JNJ-54861911 on Day 1.
Study: NCT02922400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition Assessment and Training
Description: The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
Study: NCT03432312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Nicotine mint lozenge, 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine lozenge
Description: NiQuitin mint lozenge, 4 mg
Study: NCT02040285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl & PEG-CS
Description: the day before the CTC:~* low fiber diet~* at 15.00: 2 tablets of bisacodyl (5 mg)~* at 17.00: 1 litre of PEG-CS~* liquid diet~the day of the exam:~* at home: 2 tablets of bisacodyl (5 mg)~* at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~* at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol
Description: the day before CTC:~* low fiber diet~* at 15.00: 90 ml of Iopamidol in 250 ml of water~* at 17.00: 90 ml of Iopamidol in 250 ml of water~* at 20.00: start liquid diet
Study: NCT02545075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Study: NCT00055224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threat of shock
Description: During threat, a participant could receive a shock. During safe, a participant could not receive as shock. Participants selected their highest tolerable level of shock.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threat of shock
Description: During threat, a participant could receive a shock. During safe, a participant could not receive as shock. Participants selected their highest tolerable level of shock.
Study: NCT00261300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Long term Pantoprozole trial
Study: NCT02057393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium99
Description: Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene blue
Description: Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
Study: NCT01637987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unassisted vein visualization
Description: The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wee Sight® Transilluminator
Description: The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VeinViewer® (Christie Digital Systems, Cypress, CA)
Description: VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein \& surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
Study: NCT05032248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus ointment
Description: oral gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Description: oral gel
Study: NCT02233062

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition Therapy
Study: NCT02563990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Pressure Injection
Description: Adductor canal block performed at greater than 20 psi injection pressure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Pressure Injection
Description: Adductor canal block performed at less than 15 psi injection pressure
Study: NCT01490554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous fibroblasts grafts
Description: Autologous cultured fibroblasts will be grafted in facial skin
Study: NCT04081233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical stabilization
Description: Surgical procedure utilizing any commercially available internal rib fixation system
Study: NCT02744274

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Verum acupuncture
Description: Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a de qi sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a de qi.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Description: Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a de qi sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a de qi.
Study: NCT03803267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl NCS
Description: Fentanyl (1µg/Kg)
Study: NCT05406492

Intervention type: OTHER
Intervention: Residual blood
Description: Residual blood samples(1\~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
Study: NCT03803267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl NCS
Description: Fentanyl (1µg/Kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Injectable Product
Description: atracurium (0.5mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium Injectable Product
Description: atracurium (0.5mg/kg)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: endotracheal intubation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: endotracheal intubation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia Maintenance
Description: Inhalational isoflurane in oxygen/air mixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia Maintenance
Description: Inhalational isoflurane in oxygen/air mixture

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxation
Description: atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxation
Description: atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
Study: NCT03969602

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral Therapy
Description: The biopsychosocial approach of CBT focuses on the complex interaction between psychological, social and biological factors. The biopsychosocial model assumes that health problems are hardly ever limited to just one domain of human experience but by multiple domains of human experience. CBT helps patients understand thoughts and feelings that influence behaviors. It consists of a cognitive aspect and a behavioral aspect. The cognitive aspect is based on Becks cognitive model: the way that individuals perceive a situation is more closely connected to their reaction than the situation itself. A person's cognition has impact on their mood and emotions, their bodily reactions and their behavior. The second part of cognitive behavior therapy focuses on the actual behaviors that are contributing to the problem. The goal of CBT is to identify maladaptive thoughts and change them into more realistic and constructive thoughts to modify feelings and behavior and thereby the experience of pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomedical and surgery-specific education
Description: Biomedical and surgery-specific education preoperatively and an exercise manual postoperatively.
Study: NCT01309854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fostamatinib
Description: oral tablets, 100mg (2 X 50mg) twice daily for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: oral tablets, 30mg single dose per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: oral tablets, 30mg single dose per period
Study: NCT04081233

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care typically consists of breathing exercises and pain control,often including opioids
Study: NCT04155632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
Study: NCT02467374

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Therapy
Description: BT for OCD focuses primarily on exposure with response prevention (ERP). ERP involves gradual exposure to anxiety-provoking situations (things or situations that frighten or disturb some people), and will help to prevent compulsions (repetitive behaviors).
Study: NCT04704973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic short-term psychotherapy
Description: Focused clinical functional analysis, formulation of a valued life direction includings strategies to handle obstacles, and a summarizing exercise including relapse prevention.
Study: NCT02775604

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video based/Therapists' rating of comprehensive-home-fall-hazard-checklist (vt-CHFHC)
Description: The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
Study: NCT04155632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-burst stimulation (TBS)
Description: Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
Study: NCT02475356

Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: The treatment of Mirena should comply with the local product information.
Study: NCT02403973

Intervention type: OTHER
Group type: OTHER
Intervention: IN2005E
Description: IN2005E is a validated questionnaire that measures patient satisfaction

Intervention type: OTHER
Group type: OTHER
Intervention: IN2005E
Description: IN2005E is a validated questionnaire that measures patient satisfaction
Study: NCT02775604

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Paper based/Patient self-rating of comprehensive-home-fall-hazard-checklist (pp-CHFHC)
Description: A paper version of CHFHC and other self-reported documents will be completed by the participants in their homes based on standardized verbal instruction provided by the research staff.
Study: NCT01385631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
Study: NCT03652545

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-T
Description: Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
Study: NCT01994928

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nose-mouth mask
Description: Preoxygenation using a nose-mouth mask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula oxygen
Description: Preoxygenation using high flow nasal cannula oxygen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intubation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Intubation
Study: NCT02690883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro
Description: Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG \<10.0mmol/L.
Study: NCT00920101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle counseling
Description: Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
Study: NCT00864058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg capsules
Description: A: Experimental Subjects received Actavis formulated products under fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEURONTIN® 400 mg capsules
Description: B: Active comparator Subjects received Parke-Davis's marketed product
Study: NCT03578562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted training intervention
Description: An 8-week progressive homebased training intervention with supervised booster-sessions
Study: NCT03765697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% medicated plaster
Description: Topical application at the site of skin affected by painful PHN for up to 12 hours per day (plaster-free interval at least 12 hours).
Study: NCT01600703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin, 100mg, oral, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral, single dose
Study: NCT01444066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dilation of the esophagus
Description: Esophagus will be dilated with a Savory dilator.
Study: NCT01481103

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
Study: NCT01160718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fulvestrant
Description: Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
Study: NCT01444066

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dilation of the esophagus
Description: Esophagus will be dilated with a Savory dilator.
Study: NCT04285996

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PET Scan